Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Oxeia Biopharmaceuticals Inc. operates a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. There is currently 1 pending office action for this portfolio. This 1 pending office action is the only active matter currently under review by the patent office. The prosecution is focused on a single technical advancement in the biotechnology field.
The data identifies 1 distinct examiner, DABKOWSKI, ERINNE R, as the busiest examiner. This examiner is currently handling 1 busiest examiner pending action. Because the portfolio contains only 1 distinct examiner, the prosecution process is highly centralized. This allows the company to focus its resources on addressing the specific concerns and examination style of this individual.
The current activity is confined to 1 distinct art unit. This 1 distinct art unit indicates that the pending application is being evaluated within a specific technical framework. The combination of a single examiner and a single art unit simplifies the administrative burden and allows for a targeted approach to the Biotechnology & Pharmaceuticals requirements of the office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DABKOWSKI, ERINNE R | 1 | 55.7% | +68.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17787848 | TREATMENT OF MILD TRAUMATIC BRAIN INJURY | DABKOWSKI, ERINNE R | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17787848 | TREATMENT OF MILD TRAUMATIC BRAIN INJURY | DABKOWSKI, ERINNE R | 1654 | §112 | Final Rejection | — | Pending | Jun 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOxeia Biopharmaceuticals Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Erinne R Dabkowski has the most, with 1 of Oxeia Biopharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.